Dr. Benny Liu
Dr. Liu researched NPC disease for around 7 years in the lab of Drs. John Dietschy and Stephen Turley at the University of Texas Southwestern (UTSW). In early 2006, Dr. Liu discovered cyclodextrin as a treatment for NPC disease.
Dr. Benny Liu is the Associate Division Chief of Gastroenterology at Highland Hospital in Oakland and an Assistant Clinical Professor at the University of California, San Francisco (UCSF). In addition to his work researching Niemann-Pick Type C disease, Dr. Liu's research interests include lysosomal storage diseases and cholesterol metabolism.
Discovery of Cyclodextrin
Getting Involved with NPC
Dr. Liu began researching NPC shortly after an exciting finding at UCSF that claimed allopregnanolone extended the lives of NPC mice.
Research at UTSW
Although previous studies said cyclodextrin had no effect on NPC, Dr. Liu included a cyclodextrin-only control when he repeated the UCSF lifespan experiment at UTSW.
Results of Cyclodextrin
The results of cyclodextrin in mice were very good – more than double the lifespan as well as multiple improvements to their quality of life.